← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Paratek Pharmaceuticals
Boston, MA
$7,537,005
Total funding
4
Grants
Funding over time
peak $2.3M · FY2005–13$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$7,537,005 · 4
By mechanism
U01$3,154,774 · 1
R42$2,598,685 · 1
R43$1,783,546 · 2
Investigators at Paratek Pharmaceuticals
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel Tetracycyclines as Antimalarial Drugs$1,336,905
R42 · FY2004 · AI
Novel Tetracycyclines as Antimalarial Drugs$1,261,780
R42 · FY2005 · AI
Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.$1,159,885
U01 · FY2011 · NS
Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.$1,159,885
U01 · FY2011 · NS
Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.$1,065,515
U01 · FY2010 · NS
Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.$1,065,515
U01 · FY2010 · NS
Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.$929,373
U01 · FY2009 · NS
Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.$929,373
U01 · FY2009 · NS
Novel Therapeutics for Biodefense$854,748
R43 · FY2005 · AI
Novel Therapeutics for Biodefense$829,558
R43 · FY2004 · AI
Development of Novel Tetracyclines as Antimalarial Drugs$99,240
R43 · FY2002 · AI
Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.$1
U01 · FY2013 · NS
Tetracycline derivatives as SMN2 mRNA splicing modifiers for treatment of SMA.$1
U01 · FY2013 · NS